Medical Devices — US PTAB Patent Cases
112 decisions indexed
Page 2 of 4 · 112 total
Avanos Medical, Inc. v.Stratus Medical, LLC
Petitioner Avanos Medical challenges Stratus Medical's '664 Patent, asserting that all claimed features are obvious over various combinations of prior art references in RF ablation technology. The challenge rests entirely on statutory grounds of 35 U.S.C. § 103, utilizing multiple prior art patents related to neurotomy devices.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The PTAB institution decision found a reasonable likelihood of unpatentability for several claims in the dermatological treatment patent, primarily based on anticipation by reference Mehta. The Board rejected arguments for discretionary denial and proceeded with the IPR.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted the IPR challenge against Serendia's '536 patent, finding a reasonable likelihood of unpatentability. The Board determined that prior art (Mehta) discloses the claimed depth control feature despite arguments for fixed-length needles.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found all 29 challenged claims unpatentable by a preponderance of evidence. The Board rejected the Patent Owner's argument that the invention was limited to RF neurotomy, adopting Petitioner's broader view of 'thermal ablation systems.'
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found that the claims were unpatentable over Racz, Fitz, and Lee based on obviousness (103). The Board adopted Petitioner's broad definition of 'thermal ablation systems,' rejecting the Patent Owner's narrow focus on 'RF neurotomy.'
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding that Claims 1-17 and 48-52 are unpatentable based on obviousness. The Board found that the combination of prior art references (Racz, Fitz, Lee) was an obvious modification to create functional RF neurotomy devices.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding all 27 challenged claims unpatentable based on obviousness over prior art (Racz, Fitz, Lee). The Board adopted the Petitioner's broad definition of POSA in the field of thermal ablation systems.
Imperative Care, Inc. v.INARI MEDICAL, INC.
The Board found that the claims were unpatentable under obviousness (Grounds 3 and 4), specifically over a combination of Schaffer's valve with Hartley's string or Eller's wire. The decision hinged on finding that a POSA would have had reason to make this substitution, leading to predictable results in hemostatic device design.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The Petitioner successfully demonstrated that multiple claims of the '077 patent were unpatentable over various combinations of prior art references. The Board found that a Person Having Ordinary Skill in the Art (POSA) would have been motivated to combine existing RF ablation and nasal treatment technologies.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB granted institution for ResMed Corp.'s IPR against Cleveland Medical Devices, Inc., finding a reasonable likelihood of prevailing. The Board overcame arguments regarding parallel District Court litigation by applying the Fintiv factors.
SHENZHEN ROOT TECHNOLOGY CO., LTD. et al. v.Chiaro Technology Ltd.
The PTAB denied institution of an IPR challenge against Chiaro Technology's breast pump patent (11413380) because the petitioner had filed a parallel petition in another proceeding.
Biofrontera AG et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB denied an IPR challenge brought by Biofrontera AG against Sun Pharmaceutical Industries regarding photodynamic therapy illuminators. The Board found the petitioner failed to demonstrate a reasonable likelihood of prevailing on obviousness grounds (103).
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully petitioned to institute IPR proceedings against DexCom, Inc.'s patent (11510625) regarding transcutaneous analyte measurement systems. The Board found a reasonable likelihood of prevailing on unpatentability based on alleged anticipation by prior art reference Pace for at least Claim 1.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
The PTAB denied Abbott's second IPR petition against DexCom's '625 patent. The Board ruled that the petitioner failed to demonstrate any material difference in grounds compared to a previously instituted review.
3Shape A/S et al. v.Medit Corporation et al.
3Shape A/S filed an IPR petition challenging Medit Corporation’s patent on digital dentistry technology. The petitioner argues that the claimed 3D scanning methods are obvious under 35 U.S.C. §103, based on combining prior art systems.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Jeisys Medical Inc.'s IPR challenge against Serendia, LLC's '836 patent was instituted by the PTAB. The Board determined that the Petitioner's grounds of obviousness over prior art like Ganz were plausible and warranted further proceedings. This decision moves the dispute toward a trial phase in the medical device technology space.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. filed a Petition challenging 24 claims of DexCom's '528 patent, asserting anticipation and obviousness. The challenge focuses on the combination of real-time user settable low glucose alarms with predicted non-user settable low glucose alarms in CGM systems.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
Avation Medical, Inc. v.EMKinetics, Inc.
The PTAB found all 13 challenged claims unpatentable under 35 U.S.C § 103. The Board concluded that the claimed nerve stimulation therapy was obvious over combinations of prior art, specifically citing modifications to Svihra and Amarenco using Mann and Ponsford. This decision confirms the lack of inventive step for the technology described in the patent.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
Shenzhen Root Technology Co., Ltd. et al. v.Chiaro Technology Ltd.
The PTAB issued a Final Written Decision determining that all 46 challenged claims of the '380 patent were unpatentable. The petitioner successfully argued obviousness (103) over various prior art references, including Chang, Fang, and Yuen, concerning breast pump systems.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB rejected Petitioner's obviousness arguments against the '402 patent claims (1-20) related to a thrombectomy/aspiration system. The Board adopted an intrinsic definition of 'predetermined cycle' as fixed timing, finding that prior art combining Mullins and Yang did not teach this limitation.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. successfully challenged nine claims of INARI MEDICAL's hemostasis valve patent (11697011) at the PTAB. The Board found sufficient evidence for Petitioner’s anticipation challenge against Claim 1 after adopting a broad interpretation of the term 'filament.'
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute IPR proceedings against Stratus Medical's patent, demonstrating a reasonable likelihood of success on obviousness grounds. The Board found sufficient evidence that the claimed RF neurotomy features could be achieved by combining existing prior art references.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical, Inc. successfully convinced the PTAB to institute an IPR against Stratus Medical, LLC's '688 patent. The Board found a reasonable likelihood of success based on obviousness grounds (35 U.S.C. § 103) using prior art combinations like Racz and Lee.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute an IPR against Stratus Medical regarding a neurotomy system patent (10925664). The Board found reasonable likelihood of success on the obviousness grounds, targeting claims 1-29.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.